Mar. 17 at 8:19 PM
$SABS SAB Biotherapeutics announces common stock offering, no amount given
SAB Biotherapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the proposed offering are to be sold by SAB BIO. The company intends to use the net proceeds it receives from this offering, together with its existing cash, cash equivalents and marketable securities, primarily to fund the continued development of our clinical stage product candidate, SAB-142 through ongoing and planned clinical trials, as well as for related manufacturing, regulatory, and operational activities, and for working capital and general corporate purposes. Jefferies, UBS Investment Bank, Citigroup, and Barclays are acting as joint book-running managers for the offering. Chardan is acting as lead manager.
